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Mycolic acids are essential for the survival, virulence and antibiotic resistance of the human
pathogen Mycobacterium tuberculosis. Inhibitors of mycolic acid biosynthesis, such as isoniazid
and ethionamide, have been used as efficient drugs for the treatment of tuberculosis. However,
the increase in cases of multidrug-resistant tuberculosis has prompted a search for new targets
and agents that could also affect synthesis of mycolic acids. In mycobacteria, the acyl-CoA
carboxylases (ACCases) provide the building blocks for de novo fatty acid biosynthesis by fatty
acid synthase (FAS) I and for the elongation of FAS I products by the FAS II complex to produce
meromycolic acids. By generating a conditional mutant in the accD6 gene of Mycobacterium
smegmatis, we demonstrated that AccD6 is the essential carboxyltransferase component of the
ACCase 6 enzyme complex implicated in the biosynthesis of malonyl-CoA, the substrate of the
two FAS enzymes of Mycobacterium species. Based on the conserved structure of the AccD5
and AccD6 active sites we screened several inhibitors of AccD5 as potential inhibitors of AccD6
and found that the ligand NCI-172033 was capable of inhibiting AccD6 with an IC50 of 8 mM. The
compound showed bactericidal activity against several pathogenic Mycobacterium species by
producing a strong inhibition of both fatty acid and mycolic acid biosynthesis at minimal inhibitory
concentrations. Overexpression of accD6 in M. smegmatis conferred resistance to NCI-172033,
confirming AccD6 as the main target of the inhibitor. These results define the biological role of a
key ACCase in the biosynthesis of membrane and cell envelope fatty acids, and provide a new
target, AccD6, for rational development of novel anti-mycobacterial drugs.
INTRODUCTION
Although effective chemotherapeutic agents have been
developed, Mycobacterium tuberculosis, the aetiological
agent of tuberculosis, is still a leading cause of death
worldwide, killing over two million people annually. Each
year approximately nine million people develop active
tuberculosis and this number continues to rise due to the
expanding world population and the threat posed by HIV/
AIDS. Moreover, the synergy between tuberculosis and the
AIDS epidemic (Corbett & De Cock, 1996), coupled with
the emergence of multi-drug-resistant (MDR) M. tuber-
culosis (Chopra, 1996), and more recently extensively drug-
resistant (XDR) M. tuberculosis (Gandhi et al., 2006),
mainly as a result of the lack of compliance with the six-
month multidrug chemotherapy regime, poses a serious
threat to progress in the control of tuberculosis and could
even reverse recent gains. Therefore, there is an urgent need
to identify new drug targets suitable for the development of
new anti-mycobacterial drugs.
The unusual lipid-rich cell wall of M. tuberculosis contains
several components essential for both viability and
pathogenicity (Brennan & Nikaido, 1995). This imper-
meable barrier imparts resistance against both hostile
environments and therapeutic agents, and it plays an active
role in modulating the host immune response (Karakousis
Abbreviations: ACCase, acyl-CoA carboxylase; CT, carboxyltransferase;
FAME, fatty acid methyl ester; FAS, fatty acid synthase; MAME, mycolic
acid methyl ester; MDR, multi-drug resistant.
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et al., 2004). The cell envelope of M. tuberculosis has also
provided the molecular targets for several of the major
anti-tubercular drugs currently in use such as isoniazid,
ethambutol and pyrazinamide (Zhang, 2005). Thus, the
unique structure of this cell envelope and the importance
of its integrity for the viability of the organism suggest that
the search for novel drug targets within the array of
enzymes responsible for its construction may still prove
fruitful.
Among the potentially attractive drug targets are the
enzymes that provide the building blocks for lipid
biosynthesis, the acyl-CoA carboxylases (ACCases) (Tong,
2005). These enzymes catalyse the biotin-dependent a-
carboxylation of acetyl- and/or propionyl-CoA to generate
malonyl- and methylmalonyl-CoA, respectively. In myco-
bacteria, these metabolites are used by the fatty acid
synthase I (FAS I) for the biosynthesis of membrane fatty
acids (Schweizer & Hofmann, 2004), as well as by the FAS
II and the polyketide synthases for the biosynthesis of the
complex lipids present in the cell wall, such as the long-
chain a-alkyl,b-hydroxymycolic acids (Bhatt et al., 2007),
the phthiocerol dimycocerosates (Trivedi et al., 2005) and
sulfolipids (Jackson et al., 2007). The ACCase reaction
occurs in two catalytic steps (Cronan & Waldrop, 2002); in
the first step, biotin carboxylase (BC) couples carbonate to
a biotin residue attached to a biotin carboxyl carrier
protein (BCCP) to form carboxybiotin. In the second step,
carboxyltransferase (CT) transfers the carboxyl group from
biotin to the acyl-CoA and generates the corresponding a-
carboxylated acyl-CoA. In actinomycetes, the ACCases
consist of two large polypeptides: an a-subunit that
contains the BC and the BCCP domains and a b-subunit
that contains the CT domain (Erfle, 1973; Henrikson &
Allen, 1979; Hunaiti & Kolattukudy, 1982; Rodriguez et al.,
2001; Rodriguez & Gramajo, 1999). In some cases, a third
subunit called e, a unique feature of actinomycete ACCases,
is essential for holo complex activity (Diacovich et al.,
2002; Gago et al., 2006).
All the sequenced genomes from Mycobacterium species
contain three accA genes (for a subunits AccA1–3) and six
accD genes (for b subunits AccD1–6) (http://www.ncbi.
nlm.nih.gov/genomes/lproks.cgi). So far, only two ACCase
complexes from M. tuberculosis have been characterized at
the biochemical level. ACCase 5 was reconstituted from the
biotinylated a subunit AccA3, the CT b subunit AccD5 and
the e subunit AccE5 (Gago et al., 2006; Oh et al., 2006). The
kinetics of the holo complex indicate that ACCase 5 accepts
acetyl- and propionyl-CoA as substrates, with a fivefold
preference for propionyl-CoA, suggesting that its main
physiological role is to provide methylmalonyl-CoA for the
biosynthesis of multimethyl-branched fatty acids (Gago
et al., 2006). More recently, the ACCase 6 from M.
tuberculosis was reconstituted from the AccA3 and AccD6
subunits, and the kinetic data showed that the enzyme
carboxylates acetyl-CoA and propionyl-CoA with similar
efficiency (Daniel et al., 2007). Based on the location of
accD6 in a genetic locus that contains members of the FAS
II complex, it was suggested that ACCase 6 would
preferentially work as an acetyl-CoA carboxylase providing
malonyl-CoA to the FAS II complex for the biosynthesis of
mycolic acids. However, this hypothesis was not proved
experimentally, and hence a detailed genetic and physio-
logical characterization of this enzyme was required.
For a long time, it has been predicted that bacterial
ACCases could be suitable targets for antibacterial drug
discovery (Tong, 2005). However, it was not until recently
that the first class of bacterial ACCase inhibitor with
antibacterial activity, derived from pyrrolidine dione
natural products, was characterized and proposed as a
group of promising antibacterial compounds with a novel
mode of action (Freiberg et al., 2004; Pohlmann et al.,
2005). Recently, the successful determination of the crystal
structure of AccD5 of M. tuberculosis (Lin et al., 2006)
allowed us to carry out an extensive in silico screening of
several compound databases that resulted in the identifica-
tion of a number of putative ACCase inhibitors.
In this paper, we present what is believed to be the first
genetic and physiological characterization of an essential
ACCase of mycobacteria, and propose a physiological role
for it based on the analysis of an accD6 conditional mutant
generated in Mycobacterium smegmatis. We have also
identified and characterized a novel inhibitor of AccD6,
with the ability to inhibit growth of several Mycobacterium
species, including MDR strains of M. tuberculosis.
METHODS
Bacterial strains, culture, and transformation conditions.
Escherichia coli strain DH5a (Hanahan, 1983) was used for routine
subcloning and was transformed according to Sambrook et al. (1989).
The transformants were selected on media supplemented with the
appropriate antibiotics: 20 mg chloramphenicol (Cm) ml21, 50 mg
kanamycin (Km) ml21, 20 mg gentamicin (Gm) ml21 and/or 100 mg
streptomycin (St) ml21. E. coli B strain BL21 l(DE3) and BL21 Codon
Plus RIL (Stratagene) were used for the heterologous expression of
Mycobacterium genes. M. smegmatis mc2155 is an electroporation-
proficient mutant of mc26 (Snapper et al., 1990). Liquid cultures of
M. smegmatis were grown at 37 uC in Sauton’s medium and
Middlebrook 7H9 supplemented with ADS enrichment. Antibiotics
were used at the following concentrations: Km 15 mg ml21, Gm 20 mg
ml21 and St 20 mg ml21. M. tuberculosis and other Mycobacterium
species were grown at 37 uC in Middlebrook 7H9 or 7H10 medium.
DNA manipulations and plasmid construction
Isolation of plasmid DNA, restriction enzyme digestion and agarose
gel electrophoresis were carried out by conventional methods
(Sambrook et al., 1989). Genomic DNA of M. smegmatis was
obtained as described by Connell (1994).
pPR27D6. The accD6 gene from M. smegmatis mc2155 was PCR
amplified from genomic DNA using the oligonucleotides D6rbsNde
(59-AGACCTCATATGACAATCATGGCCCCCG-39), to introduce an
NdeI site (underlined) at the translational start codon of accD6, and
D6Hind (59-CTCGCGAAGCTTATTCTGCGTCTGCTC-39), to
introduce a HindIII site (underlined) at the end of the ORF. The
PCR product was digested with NdeI and HindIII and cloned into
NdeI/HindIII-cleaved pET24b, yielding pD6MS. The M. smegmatis
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mutant allele accD6 : : aphA-3 was built on pUC19. For this an XbaI–
HindIII fragment from pD6MS was cloned in pUC19 digested with
the same enzymes, yielding pUCD6MS. The aphA-3 cassette that
confers Kmr was obtained from pUC4K and subcloned in EcoRI-
digested pGEM-T Easy; from here, a 1.2 kb NotI fragment carrying
the Kmr cassette was cloned into pUCD6MS, yielding pD6Km.
Finally, pPR27D6, the construct used for allelic exchange, was
obtained by transferring a 3.6 kb PvuII fragment from pD6Km
containing accD6 : : aphA-3 into XbaI-cut pPR27, a temperature-
sensitive (temps) mycobacterial vector carrying the counter-selectable
marker sacB and the xylE reporter gene.
pCGD6. A 2.4 kb fragment including accD6 coding sequence plus 500 bp,
both upstream and downstream of this ORF, was obtained from genomic
DNA of mc2155 by PCR using oligonucleotides D6Ms2-Xba (59-
TCTAGACGGACGGCTACCACAT-39) and D6Ms2-Hind (59-AAGCTT-
CCACCGAGGCCGAATACG-39), sequenced to confirm fidelity and
cloned in pCRBluntII-Topo (Invitrogen). From the resulting plasmids a
2.4 kb XbaI fragment was cloned into pCG76, to yield pCGD6.
pCGHD6. An NdeI–HindIII fragment from pD6MS was cloned in
pVV2 digested with the same enzymes, yielding pVVD6MS. The
vector pVV2 (Dhiman et al., 2004) is a derivative of pMV261 that
allows expression of recombinant proteins from cloned genes from
the GroEL promoter as fusions with an amino-terminal hexahistidine
epitope tag. The 1.73 kbp XbaI–SpeI fragment containing M.
smegmatis accD6 under control of the GroEL promoter was cloned
in pCG76, yielding pCGHD6.
pD6MT. accD6 was PCR amplified from the genomic DNA of M.
tuberculosis H37Rv by using the oligonucleotides D6UP (59-
AGACCTCATATGACAATCATGGCCCCCG-39), to introduce an NdeI
site (underlined) at the translational start codon of the accD6 gene, and
D6DN2 (59-CTCGCGAAGCTTATTCTGCGTCTGCTC-39), to introduce
a HindIII site (underlined) at the end of the ORF. To generate an accD6
His-tag fusion gene, the PCR product was digested with NdeI and HindIII
and cloned into NdeI/HindIII-cleaved pET24b, yielding pD6MT.
Southern blot analysis for the allelic replacement of accD6.
Approximately 10 mg genomic DNA was digested overnight with an
excess of EcoRV, and the fragments were separated by electrophoresis
through 0.7 % agarose gels. Southern blotting was carried out in 106
SSC using Hybond-N+ nylon membranes (Amersham). The probe
consisted of a 666 bp fragment of the kasB gene amplified using the
oligonucleotides 5D6EcoUP (59-TCTGGCATTCGGGCGTTACTG
AG-39) and 5D6EcoDn (59-CGGCACGGCTTCGATCTTGGTCT-
39). The Prime a Gene labelling system (Promega) and 5 mCi
(185 MBq) [a-32P]dATP were used to label the probe. Prehybridi-
zation and hybridization were carried out at 65 uC using 56 SSC, 56
Denhardt’s solution and 0.5 % SDS. Serial 15 min washes were
performed at 65 uC as follows: two washes with 26 SSC/0.1 % SDS
and two washes with 16 SSC/1 % SDS. The filter was developed and
digitalized with a Storm 840 scanner (Amersham).
Protein methods. Purified proteins were analysed by SDS-PAGE
(Laemmli, 1970). Coomassie brilliant blue was used to stain protein
bands. Protein contents were determined by the methods of Bradford
(Bradford, 1976) or Lowry with BSA as a standard.
Heterologous protein expression and purification. For the
expression and purification of M. tuberculosis His6-AccD6 and
AccA3 we followed the protocols described by Gago et al. (2006).
Enzyme assays for ACCase and CT activities
Radioactive method. ACCase activities in cell-free extracts or of in
vitro reconstituted complexes were measured by following the
incorporation of radioactive HCO{3 into acid non-volatile material,
as previously described (Bramwell et al., 1996; Diacovich et al., 2002;
Hunaiti & Kolattukudy, 1982). One unit of enzyme activity catalysed
the incorporation of 1 mmol 14C into acid-stable products min21.
Pyruvate kinase-lactate dehydrogenase (PK-LDH). The rate of ATP
hydrolysis by biotin carboxylase was measured spectrophoto-
metrically (Janiyani et al., 2001). The production of ADP was
coupled to PK and LDH, and the oxidation of NADH was monitored
at 340 nm. Assays were performed in a Dynex MRX microplate reader
as previously described (Diacovich et al., 2002). Initial velocities were
obtained from initial slopes of the recorder traces. Under the assay
conditions described, the reaction was linear for at least 3 min and the
initial rate of reaction was proportional to the enzyme concentration.
One unit of enzyme activity catalyses the formation of 1 mmol of the
respective carboxylated CoA derivative or ADP min21 under the assay
conditions described. Specific activity is expressed as units per mg of
AccA3. Initial velocities were determined with this assay at 10–
150 mM inhibitor concentrations in the presence of Km
concentrations of propionyl-CoA (100 mM) for ACCase 5 or acetyl-
CoA (500 mM) for ACCase 6. The amount of protein used for the
AccD5 assay was 0.4 mM AccA3, 0.4 mM AccD5 and 4 mM AccE5, and
for the AccD6 assay 0.8 mM AccA3 and 0.8 mM AccD6. IC50 values
were obtained by fitting the data to a sigmoid dose–response equation
using the GraphPad Prism 4.0 software.
Minimal inhibitory concentration (MIC) determination. MIC
values for the mycobacterial species used were determined by
twofold dilution in Middlebrook 7H9 broth supplemented with
glycerol and ADS and colorimetric evaluation of viability as
described by Palomino et al. (2002). M. smegmatis mc2155, M.
tuberculosis H37Rv, M. bovis BCG, and clinical isolates of MDR M.
tuberculosis AI55 and AI57, M. fortuitum, M. kansasii and M. avium
were used for this determination. Briefly, 16105 c.f.u. were used to
inoculate each well in a 96-well plate in which a twofold dilution
(100 ml final volume) of the tested compound had been made.
Rifampicin and isoniazid were used as control drugs, except for M.
fortuitum, where imipenem was used due to the intrinsic resistance
of this mycobacterium to rifampicin and isoniazid. Plates were
sealed and incubated at 37 uC for 2 days (M. smegmatis and M.
fortuitum), 5 days (M. kansasii) or 7 days (M. tuberculosis and M.
bovis BCG). Viability was estimated by adding 20 ml resazurin
(10 mg ml21 in water) followed by further incubation for 24 h. A
colour change from blue to pink indicates cell viability. The MIC was
determined as the lowest concentration of drug giving no colour
change.
The MIC of NCI-172033 for M. smegmatis overexpressing accD6 was
determined on Petri dishes containing Middlebrook 7H11 solid
medium by spreading 100–200 c.f.u. of strains MS-CGD6 and MS-
CGHD6 and the control strain MS-CG76 (Table 1). Four concentra-
tions of NCI-172033 (25, 50, 100 and 200 mM) were tested. Colonies
were counted after incubation at 30 uC for 6 days. Plates were also
screened under an optical microscope to detect pinpoint colonies and
determine colony morphology alterations. MIC99 was defined as the
concentration of the compound under test that reduced the c.f.u. to
¡1 % of the number on control plates (no compound). The
experiments were performed twice in triplicate.
Effect of NCI-172033 on mycobacterial growth. To determine
whether the compound being tested was bacteriostatic or bactericidal,
M. tuberculosis cultures containing 105 c.f.u. ml21 were incubated
with several concentrations of NCI-172033. Small aliquots (10 ml) of
control (drug-free) and drug-treated (0.5–4 times the MIC value)
cultures were withdrawn from a 96-well microtitre plate after 2 and
4 days incubation with the drug, diluted and plated on drug-free
7H11 Middlebrook medium. C.f.u. were counted after incubation at
D. G. Kurth and others
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37 uC for 3 weeks. A similar experiment was also carried out with M.
smegmatis. Samples were withdrawn after 24 or 48 h incubation with
the inhibitor (at 0.5–2 times the MIC), diluted and plated on drug-
free 7H11 Middlebrook medium. The experiments were carried out in
duplicate for two independent cultures of each of the strains under
study.
Metabolite incorporation assays. Cultures of M. smegmatis
mc2155 and of the D6DCO2 mutant were grown in 7H9 medium
supplemented with ADS at 30 or 42 uC, and at different time points
aliquots of the cultures were labelled for 1 h with L-[4,5-3H]leucine
(60 Ci mmol21), or [1-14C] acetate (59 mCi mmol21) (New England
Nuclear) at concentrations of 1 mCi ml21 (37 kBq).
[3H]Leucine was used to monitor metabolic activity. After labelling,
cells were pelleted, washed with cold water, and resuspended in 100 ml
Tris/HCl (10 mM, pH 8.0). Samples were precipitated with 6 %
perchloric acid and filtered through glass fibre filters (Millipore).
After washing the precipitates with 1 ml ethanol, radioactivity was
determined in a Beckman liquid scintillation counter.
Fatty acid biosynthesis was analysed by incorporation of [14C]acetate.
Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters
(MAMEs) were extracted as described by Kremer et al. (2000), using
aliquots from cultures containing the same number of cells. The
resulting solution of FAMEs and MAMEs was assayed for radioactiv-
ity in a Beckman liquid scintillation counter and then subjected to
TLC using silica gel plates (5735 silica gel 60F254; Merck) and
developed in hexane/ethyl acetate (9 : 1, v/v) or petroleum ether/
diethyl ether (95 : 5, v/v). Autoradiograms were produced by
overnight exposure to Kodak X-Omat AR film to reveal 14C-labelled
FAMEs and MAMEs. To analyse the effect of the inhibitors (isoniazid,
cerulenin or NCI-172033) on fatty acid biosynthesis, the compounds
were added at the corresponding concentrations 1 h before the
radioactive label.
In vitro assay for FAS I activity. The standard reaction mixture for
FAS I was composed as described by Slayden et al. (1996). It
consisted of 100 mM potassium phosphate (pH 7.0), 5 mM EDTA,
5 mM DTT, 300 mM acetyl-CoA, 100 mM NADPH, 100 mM NADH,
1 mM flavin mononucleotide, 500 mM a-cyclodextrin, 20 mM mal-
onyl-CoA, 100 000 c.p.m. [2-14C]malonyl-CoA and 100 ml of the
cytosolic enzyme preparation (1–2 mg protein) in a total volume of
500 ml. Reactions were performed in triplicate at 37 uC for 30 min
and terminated by the addition of 500 ml 20 % potassium hydroxide
in 50 % methanol and incubation at 100 uC for 30 min. Following
acidification with 300 ml 6 M HCl, the resultant 14C-labelled fatty
acids were extracted three times with petroleum ether. The organic
extracts were pooled, washed once with an equal volume of water,
and dried in a scintillation vial prior to measurement of
radioactivity.
Table 1. Bacterial strains and plasmids used in this work
Plasmids Relevant genotype and/or information* Source or reference
pET28a(+) Phagemid vector (Kmr lacZ9) for expression of recombinant proteins under control of
strong T7 transcription and translation signals
Novagen
pD6MT pET28a(+) with M. tuberculosis accD6 His-tag fusion gene, under T7 promoter control, Kmr This study
pD6MS pET28a(+) with M. smegmatis accD6 His-tag fusion gene, under T7 promoter control, Kmr This study
pD5 pET28a(+) with M. tuberculosis accD5 His-tag fusion gene, under T7 promoter control, Kmr Gago et al. (2006)
pA3 pET28a(+) with M. tuberculosis accA3 His-tag fusion gene, under T7 promoter control, Kmr Gago et al. (2006)
pUC4K Contains aphA-3 cassette that confers Kmr Vieira & Messing (1982)
pPR27 E. coli–Mycobacterium shuttle vector, oriM temps, sacB xylE Gmr Pelicic et al. (1997)
pPR27D6 pPR27 derivative carrying accD6 : : aphA-3, Gmr Kmr This study
pCG76 E. coli/Mycobacterium shuttle vector, oriM temps, Str/Spr Guilhot et al. (1994)
pCGD6 pCG76 derivative harbouring accD6 plus 500 bp, both upstream and downstream of this
ORF from M. smegmatis, Str/Spr
This study
pCGHD6 pCG76 derivative harbouring M. smegmatis accD6 His-tag fusion gene, under GroEL
promoter control, Str/Spr
This study
E. coli
DH5a E. coli K-12 F2 DlacU169 (w80lacZDM15) endA1 recA1 hsdR17 deoR supE44 thi-1 l2
gyrA96 relA1
Hanahan (1983)
BL21l(DE3) E. coli B F2 ompT r{B m
{
B (DE3) Studier & Moffatt (1986)
BL21l(DE3)
Codon Plus
E. coli B F2 ompT hsdS (r{B m
{
B ) dcm
+ TetR gal (DE3) endA Hte [argU ileY leuW], CmR Stratagene
M. smegmatis
mc2155 Fast-growing strain harbouring all plasmids used herein Snapper et al. (1990)
D6SCO1 mc2155 with pPR27D6 integrated into accD6 locus, Kmr This study
D6DCO2 Mutant containing an intrachromosomal allelic exchange at accD6 locus in presence
of pCGD6, Kmr Str/Spr
This study
MS-CG76 mc2155 harbouring pCG76, Str/Spr This study
MS-CGD6 mc2155 harbouring pCGD6, Str/Spr This study
MS-CGHD6 mc2155 harbouring pCGHD6, Str/Spr This study
*Gmr, Gentamicin resistance; Kmr, kanamycin resistance; Str, streptomycin resistance; Spr, spectinomycin resistance; Cmr, cloramphenicol
resistance; temps, temperature sensitivity.
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RESULTS
AccD6 is an essential carboxyltransferase in
M. smegmatis
In order to demonstrate that AccD6 is the CT component
of an essential ACCase involved in providing malonyl-CoA
for lipid biosynthesis in mycobacteria, we reasoned that a
conditional accD6 mutant was required. For this purpose
we used M. smegmatis as a model system, where
temperature-sensitive (temps) vectors, which allow the
rapid and efficient construction of conditional mutants, are
available (Guilhot et al., 1992).
The essentiality of accD6 was first suggested by the
impossibility of generating a knockout mutant through a
two-step homologous recombination strategy (Pelicic et
al., 1996). For the first recombination step, the temps
plasmid pPR27D6, harbouring a disrupted copy of the
accD6 gene (accD6 : : aphA-3), was introduced into M.
smegmatis by electroporation and one of the Kmr
transformants was plated at 42 uC to promote plasmid
recombination. PCR analysis of the chromosomal DNA
from several Kmr XylE+ colonies indicated that two of
them resulted from a single recombination event in the 39
end of the chromosomal copy of accD6 (Fig. 1b); the other
eight clones most probably arose from illegitimate
recombination. To select for the intra-chromosomal allelic
exchange, one of the M. smegmatis colonies, containing the
correct integration of pPR27D6 and named D6SCO1, was
grown in LB-Km at 30 uC and plated on LB-Km-Suc plates
at 30 uC (Pelicic et al., 1997). None of the thousands of
colonies screened exhibited the expected phenotype (Kmr
Sucr, white after catechol spraying), strongly suggesting
that accD6 was an essential gene. Thus, to allow for the
second recombination event to take place we constructed
an accD6 merodiploid strain by introducing pCGD6 into
D6SCO1. In this plasmid accD6 can only be expressed from
its own promoter sequences, since pCG76 is not an
expression vector. One of the Kmr Str transformants, called
D6DCO2, was grown at 30 uC in LB-Km-St and plated on
LB-Km-St-Suc plates at 30 uC. At least 30 % of the colonies
grown in these conditions were also white after spraying
Fig. 1. Allelic exchange of the accD6 locus of M. smegmatis. (a–c) Genetic organization, partial restriction map and expected
hybridization profiles of the accD6 chromosomal region in (a) the wild-type strain mc2155, (b) the single crossover strain
D6SCO1 and (c) the M. smegmatis D6DCO2 conditional mutant. Oligonucleotides used to confirm single and double
crossover events by PCR are indicated. (d) Southern blot analysis of M. smegmatis accD6 mutants. Three mutants were picked
at random (1, 2 and 3); chromosomal DNA was digested with EcoRV and probed for hybridization with a labelled 666 bp
fragment corresponding to the 59 region of kasB.M. smegmatis mc2155 DNA was included as a control (wt). Molecular masses
are indicated in kb.
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with catechol, indicating that they had undergone intra-
chromosomal allelic exchange (Fig. 1c). Three of these
colonies were screened by PCR (see Supplementary Fig. S1,
available with the online version of this paper) and it was
confirmed by Southern blot analysis that they all had the
correct allelic exchange at the chromosomal accD6 locus
(Fig. 1d). These experiments support the idea that accD6 is
an essential gene in M. smegmatis and strongly suggest that
this gene, which is considered part of the fasII operon
(Daniel et al., 2007), is most probably an independent
transcription unit.
To confirm that AccD6 was essential for M. smegmatis
growth, we investigated the ability of strain D6DCO2 to
survive at 42 uC, a temperature at which the rescue plasmid
pCGD6 is unable to replicate. The growth characteristics of
mc2155/pCG76 and of the accD6 temps mutant D6DCO2
at 30 and 42 uC are presented in Fig. 2(a, b). As expected, at
30 uC, strain D6DCO2 exhibited the same growth char-
acteristics as the control strain mc2155/pCG76. However,
at 42 uC, the D6DCO2 mutant replicated for two to three
generations and then stopped dividing after ~12 h (OD600
0.7) (Fig. 2a). The growth of D6DCO2 for two to three
generations after the temperature shift is consistent with
the way the temps plasmid is cured, as has been described
for the pAL5000 derivative plasmids (Guilhot et al., 1992).
Soon after the D6DCO2 culture stops growing, a large
proportion of cells can no longer replicate, consistent with
the loss of the AccD6-encoding plasmid and therefore with
the loss of ACCase 6 activity. This effect is reflected by a
dramatic drop of c.f.u. ml21 in the culture; e.g. 2 h after
the culture stopped growing, fewer than 30 % of the cells
are still able to yield colonies when plated on LB agar at
30 uC (Fig. 2b). All these colonies also grew on LB-St agar,
indicating that all of them still contain pCGD6 (data not
shown). These results unambiguously show that AccD6
plays an essential role in the physiology of this bacterium.
Characterization of the accD6 conditional mutant
of M. smegmatis
To study the physiological role of the ACCase 6 complex
we carried out [14C]acetate labelling experiments using the
accD6 conditional mutant D6DCO2 and the control strain
mc2155/pCG76 and analysed their lipid content by TLC. As
shown in Fig. 2(c), when both strains were growing at the
same rate at the restrictive temperature of 42 uC (labelled
as 23 h in Fig. 2c), there was no difference in the content
of fatty acids or mycolic acid in their membranes; however,
after the conditional mutant stopped growing (OD600 0.7
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Fig. 2. Growth characteristics and lipid composition of the accD6
conditional mutant D6DCO2 incubated at 30 and 42 6C. (a)
Growth curves of strains mc2155/pCG76 ($, #) and D6DCO2
(., g) incubated at 30 6C (black symbols) and 42 6C (white
symbols). Saturated cultures grown at 30 6C were diluted in fresh
7H9 medium supplemented with ADS to an OD600 of 0.1 and
further incubated at 30 or 42 6C. The arrow indicates growth
arrest of D6DCO2. (b) At different time points, the number of
viable cells of D6DCO2 in the cultures grown at 30 6C ($) and
42 6C (#) was evaluated by plating serial dilutions onto LB plates
at 30 6C. (c) Saturated cultures of strains mc2155/pCG76 and
D6DCO2 were diluted in fresh 7H9 medium and incubated at
42 6C. At ”3, 1, 2 and 4 h before or after D6DCO2 stopped
growing (see a), aliquots from both cultures containing the same
number of cells were labelled with [14C]acetate for 1 h at 42 6C.
One half of each sample was used to study the fatty acid and
mycolic acid compositions of the strains by TLC (solvent system:
hexane/ethyl acetate, 10 : 1).
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or ~12 h of growth at 42 uC), de novo synthesis of both
molecules was progressively affected until there was almost
no incorporation of the labelled substrate (Fig. 2c). To
confirm that this phenotype was related to the loss of the
acetyl-CoA carboxylase activity of ACCase 6, cell-free
extracts were prepared from the control strain and the
D6DCO2 conditional mutant growing at 42 uC and assayed
for this enzyme activity. In correlation with the expected
loss of pCGD6, the levels of acetyl-CoA carboxylase in
D6DCO2 showed a progressive and dramatic decrease after
the culture stopped growing, in contrast with the steady
levels of activity in the control strain (Fig. 3a). To confirm
that the loss in ACCase activity in the mutant strain was
not related to a pleiotropic effect caused by an immediate
death of those cells that lost the plasmid, we performed
[3H]leucine labelling experiments at different time points in
the wild-type and the mutant in order to determine the
levels of metabolic activity in the cultures. As shown in Fig.
3(b), 2 h after the D6DCO2 strain stopped growing, the
metabolic activity of the cells was still comparable to that of
strain mc2155/pCG76 (Fig. 3b); however, at this point the
ACCase activity had already dropped 70 % compared to
the wild-type strain (Fig. 3a). At later time points the drop
in ACCase activity could be correlated with a decrease in
cell viability, as indicated by the reduction of [3H]leucine
incorporation compared to the control strain (Fig. 3b). To
further support the observation that after 2 h the mutant
cultures stop growing but the cells remain metabolically
active, we measured the cytoplasmic levels of the NADP-
dependent malic enzyme at different time points
(Supplementary Fig. S2). Altogether, these results dem-
onstrate that at least in M. smegmatis, AccD6 is part of an
essential ACCase that provides the substrate, malonyl-CoA,
for fatty acid and mycolic acid biosynthesis and that none
of the other ACCases present in this bacterium can
compensate for the loss of this activity.
Identification and characterization of an AccD6
inhibitor
Having demonstrated that AccD6 is the CT subunit of a
key ACCase in mycobacteria, we set out to identify a ligand
that could inhibit this protein and hence the synthesis of
the malonyl-CoA needed for lipid biosynthesis. Based on
the similarity of substrate specificities of ACCase 5 and
ACCase 6 and on the crystallographic data of the active
sites of AccD5 (Lin et al., 2006) and AccD6 (results to be
published elsewhere), implying a very similar acyl-CoA
binding pocket, we reconstituted the M. tuberculosis
ACCase 6 complex in vitro and tested the inhibitory effect
of the hit compounds identified in the first round of in
silico inhibitor screening carried out against the AccD5
active site (Lin et al., 2006). Among all the compounds
tested, only one, NCI-172033 (Fig. 4a), showed extensive
enzyme inhibition when tested against the AccD6 subunit
by using the malate dehydrogenase/citrate synthase
coupled assay (data not shown). As the selection of this
compound was originally based on the AccD5 structure, we
compared its inhibition profile on both ACCase 5 and
ACCase 6 complexes by the pyruvate kinase coupled
method (Janiyani et al., 2001). Both ACCase complexes
were reconstituted from their recombinant expressed
subunits and their activity was determined in the presence
of different concentrations of the inhibitor. These studies
showed that NCI-172033 produced a strong inhibition of
the ACCase 6 activity, with IC50 values of approximately
8 mM. In comparison, the IC50 for ACCase 5 was almost
10-fold higher (70 mM) than the value obtained for
ACCase 6 (Fig. 4b). The same results were obtained with
the reconstituted ACCase 6 from M. smegmatis (data not
shown).
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Fig. 3. (a) Loss of acetyl-CoA carboxylase activity in the D6DCO2
mutant strain at restrictive growth temperature. Cell-free extracts
were prepared from strains mc2155/pCG76 and D6DCO2
growing at 42 6C (”3, 2, and 4 h before or after D6DCO2
stopped growing), and acetyl-CoA carboxylase activity was
determined for each sample as indicated in Methods. Results are
the means of three independent experiments. (b) Determination of
metabolic activity by incorporation of [3H]leucine. At different time
points aliquots of mc2155/pCG76 and D6DCO2 cultures growing
at 42 6C were labelled for 1 h with [3H]leucine and the
radioactivity incorporated into the cells was measured as indicated
in Methods. The results were normalized by OD600 and are the
means of three independent experiments.
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Anti-mycobacterial activity of NCI-172033
To continue with the characterization of NCI-172033 in
vivo, the compound was tested for its anti-mycobacterial
activity against a set of fast- and slow-growing mycobac-
terial species. NCI-172033 was active against M. tuber-
culosis H37Rv, M. bovis BCG, M. fortuitum, M. kansasii and
M. avium, with MIC values ranging between 12.5 and
25 mM, except for M. smegmatis, with a MIC value of
100 mM (Table 2). It is important to point out that two
clinical isolates of MDR M. tuberculosis were also inhibited
by NCI-172033 at the same concentration as M. tuber-
culosis H37Rv (25 mM). Rifampicin and isoniazid were
used as control drugs, and all the species used for this assay,
except for the two MDR strains and M. fortuitum, were
inhibited at the previously reported concentrations of these
two anti-mycobacterial drugs (Palomino et al., 2002).
These results indicate that NCI-172033 exhibits anti-
mycobacterial activity on both drug-susceptible and
drug-resistant strains, and that it has no cross-resistance
with the two major anti-tubercular drugs currently in use.
To determine if NCI-172033 was bacteriostatic or bacter-
icidal, cultures of M. tuberculosis H37Rv were exposed for 2
or 4 days to different concentrations of the inhibitor, and
the number of viable cells, from samples obtained before
and after the treatment, was determined in antibiotic-free
medium by c.f.u. counts. At the MIC (25 mM), the same
number of c.f.u. that had been inoculated (104 c.f.u. ml21)
was recovered after the treatment, indicating that at this
concentration the compound acts as a tuberculostatic
agent. However, at concentrations above the MIC (50 and
100 mM), the compound showed a clear tuberculocidal
effect: the c.f.u. counts from both cultures declined 10-fold
after 48 h of drug exposure and 100-fold after 96 h.
Analogous results were obtained with M. smegmatis, where
a bacteriostatic effect of the compound was observed at 100
mM (MIC), while a severe bactericidal effect was observed
after the treatment of the cultures with 200 mM NCI-
172033 (c.f.u. counts declined more than 100-fold after 24
or 48 h of drug exposure) (Supplementary Fig. S3). These
results confirm that this antimicrobial agent behaves as a
typical bactericidal compound (Walsh, 2003).
NCI-172033 affects fatty acid and mycolic acid
biosynthesis at similar rates
Considering that NCI-172033 is a potent inhibitor of
ACCase 6, we hypothesized that, in vivo, the bactericidal
property of this molecule was related to the inhibition of
malonyl-CoA biosynthesis, the substrate of the FAS I and II
systems. To validate this hypothesis we studied the effect of
increasing concentrations of NCI-172033 on the de novo
synthesis of fatty acids in M. tuberculosis and M. smegmatis.
In both cases, mid-exponential-phase cultures were grown
in the presence of increasing concentrations of NCI-172033
and labelled with [14C]acetate. Fatty acids and mycolic acids
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Fig. 4. (a) Chemical structure of NCI-172033. (b) IC50 deter-
mination. ACCase activity of AccD5 ($) and AccD6 (.) was
measured using the pyruvate-kinase-coupled enzyme assay at
different concentrations of NCI-172033 and Km concentration of
the acyl-CoA substrate. IC50 values of 8 mM for the ACCase 6
complex and 78 mM for the ACCase 5 complex were determined.
Results are the means of at least four independent experiments
with a standard error that was within ±5% of the mean.
Table 2. MIC determination for NCI-172033, using several
mycobacterial species
16105 c.f.u. were used to inoculate Middlebrook 7H9 supplemented
with ADS (10 % v/v) in a 96-well plate containing twofold dilutions of
the tested compound. Plates were sealed and incubated at 37 uC for
2 days (M. smegmatis and M. fortuitum), 5 days (M. kansasii) or
7 days (M. tuberculosis and M. bovis BCG). Viability was estimated by
adding resazurin followed by further incubation for 24 h. Colour
change from blue to pink indicated viability. MIC was determined as
the lowest concentration of drug giving no colour change.
Strain MIC (mM)
M. tuberculosis H37Rv 25
M. tuberculosis AI55 25
M. tuberculosis AI57 25
M. bovis BCG 25
M. kansasii 25
M. fortuitum 12.5
M. avium 12.5
M. smegmatis mc2155 100
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were extracted and analysed by TLC. As shown in Fig. 5, in
both micro-organisms, de novo synthesis of these macro-
molecules was inhibited at similar rates, suggesting that
inhibition of malonyl-CoA biosynthesis was the most likely
reason for the absence of newly synthesized fatty acids and
mycolic acids. However, inhibition of FAS I by NCI-
172033 could also result in a strong inhibition of
[14C]acetate incorporation into both macromolecules.
Therefore, in order to narrow down the in vivo target
candidates of NCI-172033, we measured the activities of
both ACCase and FAS I in cell-free extracts prepared from
M. smegmatis cultures that had been pre-incubated in the
presence of the inhibitor. As shown in Fig. 6, the acetyl-
CoA-dependent ACCase activity of the treated cell extracts
showed ~50 % inhibition as compared with the non-
treated extract, whereas the FAS I activity was not affected.
These results strongly suggest that the inhibition of fatty
acid biosynthesis in the cultures treated with NCI-172033
occurs by inhibition of an ACCase, most probably ACCase
6, that provides malonyl-CoA to FAS I and FAS II.
AccD6 as the in vivo target of NCI-172033
To unambiguously demonstrate that AccD6 was the main
target for the growth-inhibitory effect of NCI-172033, we
carried out MIC99 determinations on M. smegmatis strains
containing extra copies of accD6. Our results showed that
growth on solid medium of the control strain MS-CG76
was not altered by the presence of a 25 mM concentration
of the inhibitor when compared with growth on control
plates (no inhibitor). At 50 mM NCI-172033, the number
of colonies was the same as on the control plate, although
we did observe a reduction in colony size. As expected, at
100 and 200 mM NCI-172033 no colonies were present on
the plates. Remarkably, in agreement with our hypothesis,
the strains overexpressing AccD6 (MS-CGD6 and MS-
CGHD6) grew normally at all the concentrations tested.
Unfortunately, we could not assay higher concentrations of
the inhibitor because of its low solubility above 200 mM.
These results provide compelling evidence that over-
expression of accD6 protects M. smegmatis from the effect
of NCI-172033, validating AccD6 as the in vivo target of
this inhibitor.
DISCUSSION
In this study we demonstrated by genetic means that
accD6, the gene encoding the CT subunit of ACCase 6, is
an essential locus in M. smegmatis (Fig. 1). Moreover, by
constructing an accD6 conditional mutant we were able to
show that the physiological role of ACCase 6 is to provide
malonyl-CoA for fatty acid and mycolic acid biosynthesis
(Figs 2 and 3). This is the second ACCase unambiguously
characterized in actinomycetes whose physiological role is
that of an acetyl-CoA carboxylase; the first one, called
ACC, was studied in Streptomyces coelicolor, where it was
demonstrated that it provides malonyl-CoA for both fatty
acid and polyketide biosynthesis (Rodriguez et al., 2001).
Studies in Corynebacterium glutamicum, whose genome
Fig. 5. Dose–response effects of NCI-172033 on fatty acid and mycolic acid biosynthesis in M. smegmatis (a) and M.
tuberculosis (b). The inhibitory effect on the incorporation of [14C]acetate was assayed by labelling the individual cultures in the
presence of increasing concentrations of NCI-172033 and inhibitory concentrations of isoniazid and cerulenin. The
corresponding FAMEs and MAMEs were isolated and analysed by TLC.
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encodes four CT subunits, suggested that AccD1 is the CT
subunit of the essential ACCase complex (Gande et al.,
2004). However, a mutant in this subunit is still able to
grow on minimal medium, suggesting that more studies
are needed to assign a clear physiological role to this
subunit.
In vitro studies by Gago et al. (2006) showed that the ACCase
5 of M. tuberculosis has the ability to carboxylate propionyl-
or acetyl-CoA at similar rates. M. smegmatis also contains
orthologues of the genes encoding ACCase 5, suggesting that
it also has a second ACCase complex, besides ACCase 6, with
the ability to carboxylate acetyl- and propionyl-CoA. This
situation raised the notion that these enzyme complexes
could complement each other for their function in
generating malonyl-CoA for fatty acid biosynthesis.
However, our results show conclusively that this is not the
case and that, in vivo, ACCase 6 is the dedicated acetyl-CoA
carboxylase of M. smegmatis. Furthermore, taking into
account that the genetic background of the ACCases of M.
tuberculosis and M. smegmatis is highly conserved and
considering that accD6 has also been predicted as an
essential gene in M. tuberculosis (Sassetti et al., 2003), we
could predict that the CT subunit AccD6 could be
considered as a new target for the development of a new
class of anti-mycobacterial compounds.
By testing nine compounds that had been identified by in
silico docking studies as putative inhibitors of the CT
AccD5 (Lin et al., 2006), we found that NCI-172033, a
poor inhibitor for AccD5, turned out to be a potent
inhibitor of AccD6 (Fig. 4b). In the literature, only two
compounds with strong inhibitory activities against
prokaryotic acetyl- or acyl-CoA carboxylases have been
characterized in detail: CPD1 (Moraimide B), which
inhibits the E. coli ACCase with a Ki of 0.005 mM (Freiberg
et al., 2004), and NCI-65828, which inhibits M. tuberculosis
ACCase 5 with a Ki of 13.1 mM (Lin et al., 2006).
NCI-172033 is also the first inhibitor of an ACCase with
proven anti-mycobacterial properties. Recently, an inhib-
itor (NCI-65828) of AccD5, the b subunit of the ACCase 5
complex of M. tuberculosis, was identified; however, this
ligand only inhibited M. tuberculosis growth at MIC values
.250 mM. In contrast, the compound characterized in this
work, NCI-172033, showed a more potent anti-bacterial
effect (MICs between 12.5 and 25 mM) against a broad
range of Mycobacterium strains, including two MDR strains
of M. tuberculosis (Table 2). So far, only one group of
compounds, the pyrrolidine dione antibiotics, has shown
such promising antibacterial properties (Freiberg et al.,
2004; Pohlmann et al., 2005). However, at least one of
them, Moiraimide B, was not efficacious against
Mycobacterium (unpublished results). Although the chem-
ical nature of NCI-172033 indicates that this compound
could not be considered as a new lead, it is relevant to note
that the rational approach followed to identify this ligand,
using the active site of AccD5 for in silico docking of large
libraries of compounds, could also be followed with the
recently solved crystal structure of AccD6 (data to be
published elsewhere) to select new and more potent
compounds.
Although the inhibition of acetate incorporation and the in
vitro inhibitory activity of NCI-172033 on the AccD6 of M.
tuberculosis and M. smegmatis strongly suggest that ACCase
6 is the primary target of action of this drug in vivo, similar
results would be obtained if the compound also inhibited
FAS I. By treating exponentially growing cultures with
inhibitory concentrations of the drug and measuring
ACCase, PCCase and FAS I activity (Fig. 6), we were able
to demonstrate that ACCase, but not FAS I, is the target of
NCI-172033. It is important to bear in mind that M.
tuberculosis has six ACCases (Cole et al., 1998), and that at
least two of them, ACCases 5 and 6, can utilize acetyl- and
propionyl-CoA as substrates (Daniel et al., 2007; Gago et al.,
2006; Oh et al., 2006). Considering that the IC50 of NCI-
172033 for ACCase 5 is almost ten times higher than that for
ACCase 6, it is not surprising that we can still detect acetyl-
and propionyl-CoA carboxylase activity in cell-free extracts
prepared from cultures pre-incubated with the drug.
Multiple copies of accD6, under the transcriptional control
of its own promoter or the GroEL promoter, increased the
MIC99 of NCI-172033 for the wild-type strain M.
smegmatis mc2155 at least twofold, validating AccD6 as
the in vivo target of NCI-172033. This result, together with
the in vitro inhibitory effect of NCI-172033 on AccD6
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Fig. 6. In vivo effect of NCI-172033 on the ACCase, PCCase
and FAS I activities of M. smegmatis. Cultures of M. smegmatis
were incubated in the presence of 100 mM NCI-172033 and the
relative acetyl- and propionyl-CoA-dependent carboxylases and
FAS I activities determined in the cell-free extracts. Cerulenin, a
known inhibitor of the b-ketoacyl synthase domain in type I
synthases, was used as a control.
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(Fig. 4b) and the in vivo inhibitory effect of this compound
on the ACCase activity (Fig. 6) and on fatty acid and
mycolic acid biosynthesis (Fig. 5), strongly suggests that the
main mechanism by which NCI-172033 works as a
tuberculocidal agent is through the inhibition of a
dedicated acetyl-CoA carboxylase activity, ACCase 6 being
the best candidate.
In conclusion, we have demonstrated that AccD6 is an
essential component of a dedicated acetyl-CoA carboxylase
in Mycobacterium and therefore a good target for
developing a novel class of inhibitors that affect fatty acid
biosynthesis. Moreover, we identified NCI-172033 as a
potent inhibitor of AccD6 and found that this compound
is the first inhibitor of an ACCase with anti-mycobacterial
properties, (Table 2). This work provides a solid founda-
tion for the discovery of more potent ACCase inhibitors as
novel anti-tuberculosis therapeutic agents.
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